Our study is an advancement over previous ones due to the incorporation of variables from up-to-date peer-reviewed studies considering the type of pathogenic variant (BRCA1 or BRCA2), age at primary breast cancer diagnosis, breast cancer subtype and stage, status of systemic treatment received. This evidence concerns the gene BRCA2 and breast cancer.